CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,450 enrolled
Drug / intervention
RapidTEG testprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01228058
NCT01228058N/ACompleted

A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients

The University of Texas Health Science Center, Houston·observational·Posted Oct 25, 2010·Updated Dec 18, 2012

In Brief

An observational study evaluating RapidTEG test for Coagulopathy. Completed, enrolled 1,450 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality. TEG has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products and preclinical data suggest that TEG is both more sensitive and specific than PT or PTT for coagulation abnormalities. Based on the preclinical work led by Dr. Holcomb, our hypothesis is that the Rapid TEG will help to identify these coagulopathic patients earlier, allow for rapid MT protocol activation, and assist in developing data driven blood product transfusion guidelines.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoagulopathy
CountriesUnited States

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2010
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.7 years ago

Interventions

RapidTEG testprocedure

The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).